Clinical Trial: GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Patients with Type 2 Diabetes.
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Diabetes Mellitus, Type 2
Study Type: OBSERVATIONAL
Official Title: Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium-glucose Cotransporter-2 Inhibitors (SGLT2is) Combination Therapy and Major Adverse Cardiovascular Events After Acute Myocardial Infarcti
Brief Summary:
Management of type 2 diabetes mellitus (T2DM) has evolved from a glucocentric to a cardiometabolic approach.Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce cardiovascular and kidney outcomes in T2DM patients with a low hypoglycemia risk.The T2DM di per se still carries a higher risk of mortality and major cardiovascular complications, doubling the case fatality rate.Tacking that GLP-1RAs and SGLT2is have different mechanisms of action,…
Read more